GPR160

Summary

GPR160 (G protein-coupled receptor 160, HGNC:23693) is a protein-coding gene on chromosome 3q26.2, encoding Probable G-protein coupled receptor 160 (Q9UJ42). Orphan receptor.

Predicted to enable G protein-coupled receptor activity. Predicted to be involved in G protein-coupled receptor signaling pathway. Located in plasma membrane. Part of receptor complex.

Source: NCBI Gene 26996 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 40 total
• Druggable target: yes
• MANE Select transcript: NM_014373

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23693
Approved symbol	GPR160
Name	G protein-coupled receptor 160
Location	3q26.2
Locus type	gene with protein product
Status	Approved
Aliases	GPCR150, GPCR1
Ensembl gene	ENSG00000173890
Ensembl biotype	protein_coding
Entrez	26996

Gene structure

Transcript identifiers

Ensembl transcripts: 55 — 50 protein_coding, 5 protein_coding_CDS_not_defined

ENST00000355897, ENST00000473675, ENST00000476668, ENST00000478364, ENST00000482710, ENST00000482813, ENST00000485735, ENST00000491740, ENST00000492492, ENST00000492924, ENST00000900470, ENST00000900471, ENST00000900472, ENST00000900473, ENST00000900474, ENST00000900475, ENST00000900476, ENST00000900477, ENST00000900478, ENST00000900479, ENST00000900480, ENST00000900481, ENST00000900482, ENST00000900483, ENST00000914748, ENST00000914749, ENST00000914750, ENST00000914751, ENST00000914752, ENST00000914753, ENST00000914754, ENST00000914755, ENST00000914756, ENST00000914757, ENST00000914758, ENST00000914759, ENST00000914760, ENST00000914761, ENST00000914762, ENST00000914763, ENST00000914764, ENST00000914765, ENST00000914766, ENST00000914767, ENST00000914768, ENST00000914769, ENST00000914770, ENST00000914771, ENST00000914772, ENST00000914773, ENST00000949599, ENST00000949600, ENST00000949601, ENST00000949602, ENST00000949603

RefSeq mRNA: 1 — MANE Select: NM_014373 NM_014373

CCDS: CCDS3211

Canonical transcript exons

ENST00000355897 — 4 exons

Exon	Start	End
ENSE00001215899	170079774	170079897
ENSE00001215909	170038915	170039043
ENSE00001434558	170083905	170085392
ENSE00001549402	170037995	170038215

Expression profiles

Bgee: expression breadth ubiquitous, 208 present calls, max score 98.91.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.3141 / max 1294.1085, expressed in 1120 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
39702	8.3693	1053
39705	2.7950	432
39704	1.7906	485
39703	0.2528	126
39706	0.0757	21
39707	0.0144	3
39710	0.0076	2
39709	0.0051	1
39708	0.0038	1

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	98.91	gold quality
mucosa of sigmoid colon	UBERON:0004993	97.50	gold quality
colonic mucosa	UBERON:0000317	97.22	gold quality
rectum	UBERON:0001052	97.14	gold quality
corpus epididymis	UBERON:0004359	96.47	gold quality
duodenum	UBERON:0002114	96.40	gold quality
bone marrow	UBERON:0002371	96.34	gold quality
jejunal mucosa	UBERON:0000399	95.63	gold quality
kidney epithelium	UBERON:0004819	95.17	gold quality
bone marrow cell	CL:0002092	94.95	gold quality
mucosa of transverse colon	UBERON:0004991	94.54	gold quality
trabecular bone tissue	UBERON:0002483	92.49	gold quality
oocyte	CL:0000023	91.09	gold quality
adult mammalian kidney	UBERON:0000082	90.90	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.43	gold quality
secondary oocyte	CL:0000655	90.18	gold quality
epithelial cell of pancreas	CL:0000083	89.91	gold quality
kidney	UBERON:0002113	89.33	gold quality
colonic epithelium	UBERON:0000397	89.21	gold quality
gall bladder	UBERON:0002110	89.21	gold quality
monocyte	CL:0000576	89.08	gold quality
leukocyte	CL:0000738	88.93	gold quality
blood	UBERON:0000178	88.64	gold quality
palpebral conjunctiva	UBERON:0001812	88.21	gold quality
pylorus	UBERON:0001166	88.11	gold quality
small intestine	UBERON:0002108	88.01	gold quality
pancreatic ductal cell	CL:0002079	87.86	gold quality
small intestine Peyer’s patch	UBERON:0003454	87.85	gold quality
bronchial epithelial cell	CL:0002328	87.79	gold quality
renal medulla	UBERON:0000362	87.54	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-11121	yes	569.16
E-HCAD-10	yes	19.40
E-MTAB-5061	yes	18.72
E-ANND-3	yes	16.55
E-GEOD-125970	yes	15.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

34 targeting GPR160, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-642A-3P	99.23	67.67	1258
HSA-MIR-642B-3P	99.23	67.67	1258
HSA-MIR-2054	99.20	68.89	1699
HSA-MIR-3973	99.20	69.19	1990
HSA-MIR-10B-3P	99.04	66.98	988
HSA-MIR-129-1-3P	98.86	68.41	779
HSA-MIR-129-2-3P	98.86	68.41	779
HSA-MIR-4662A-5P	98.48	67.18	1007
HSA-MIR-144-5P	97.66	69.90	531
HSA-MIR-5000-5P	97.40	66.11	1055
HSA-MIR-6886-3P	96.96	66.36	844
HSA-MIR-382-5P	96.71	65.90	762
HSA-MIR-582-3P	96.69	67.38	1019

Literature-anchored findings (GeneRIF, showing 3)

• Our data suggest that the expression level of endogenous GPR160 is associated with the pathogenesis of prostate cancer (PMID:26871479)
• these findings suggest an important role of GPR160 in regulating the entry of BCG into macrophages by targeting the ERK signaling pathway. (PMID:27259691)
• GPR160 is a potential biomarker associated with prostate cancer. (PMID:34168114)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	gpr160	ENSDARG00000038700
mus_musculus	Gpr160	ENSMUSG00000037661
rattus_norvegicus	Gpr160	ENSRNOG00000009487

Protein

Protein identifiers

Probable G-protein coupled receptor 160 — Q9UJ42 (reviewed: Q9UJ42)

Alternative names: G-protein coupled receptor GPCR1

All UniProt accessions (5): Q9UJ42, C9J0J1, C9JBW1, C9JTZ7, C9JUZ9

UniProt curated annotations — full annotation on UniProt →

Function. Orphan receptor.

Subcellular location. Cell membrane.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_055188* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR042353	GPR160	Family

UniProt features (17 total): topological domain 8, transmembrane region 7, chain 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UJ42-F1	76.87	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (1): 8

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 139 (showing top): CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, chr3q26, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, HOOI_ST7_TARGETS_DN, MORI_PLASMA_CELL_UP, RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_UP, RODRIGUES_DCC_TARGETS_DN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, MODULE_342, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP, GAVIN_FOXP3_TARGETS_CLUSTER_P3, MASSARWEH_TAMOXIFEN_RESISTANCE_UP, GOCC_RECEPTOR_COMPLEX, GARY_CD5_TARGETS_UP

GO Biological Process (2): signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186)

GO Molecular Function (2): G protein-coupled receptor activity (GO:0004930), protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), signaling receptor complex (GO:0043235), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
binding	1
membrane	1
cell periphery	1
protein-containing complex	1
cellular anatomical structure	1

Protein interactions and networks

STRING

590 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPR160	SEC62	Q99442	570
GPR160	CARTPT	Q16568	547
GPR160	GPR142	Q7Z601	535
GPR160	SAMD7	Q7Z3H4	530
GPR160	OTOS	Q8NHW6	469
GPR160	KLHL8	Q9P2G9	450
GPR160	BBOF1	Q8ND07	448
GPR160	GPR173	Q9NS66	442
GPR160	MYNN	Q9NPC7	435
GPR160	BNIPL	Q7Z465	435
GPR160	NMRK2	Q9NPI5	423
GPR160	TMEM45B	Q96B21	418
GPR160	GPR146	Q96CH1	417
GPR160	COPS9	Q8WXC6	412
GPR160	OR51E1	Q8TCB6	409

IntAct

20 interactions, top by confidence:

A	B	Type	Score
PRKCA	GPR160	psi-mi:“MI:0915”(physical association)	0.560
YWHAG	GPR160	psi-mi:“MI:0915”(physical association)	0.560
SETDB1	GPR160	psi-mi:“MI:0915”(physical association)	0.560
LMO3	GPR160	psi-mi:“MI:0915”(physical association)	0.560
GPR160	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
RAMP1	GPR160	psi-mi:“MI:0915”(physical association)	0.400
RAMP2	GPR160	psi-mi:“MI:0915”(physical association)	0.400
GPR160	RAMP2	psi-mi:“MI:0915”(physical association)	0.400
RAMP3	GPR160	psi-mi:“MI:0915”(physical association)	0.400
GPR160	FUT7	psi-mi:“MI:0914”(association)	0.350

BioGRID (3): GPR160 (Synthetic Lethality), FUT7 (Affinity Capture-MS), RNPEP (Affinity Capture-MS)

ESM2 similar proteins: A0A494BZU4, A0A7H0DND7, A0JNG0, A2T345, A4IIV4, C4QM85, E7F594, G5EDX4, O02051, O45306, P0DP42, P0DST5, P0DST6, P21061, P24763, P34362, P34363, P53053, Q09282, Q0II41, Q10907, Q11071, Q11085, Q13571, Q20249, Q297K8, Q2KHT4, Q2KJA5, Q32KQ5, Q5DC12, Q5GH77, Q5PQM0, Q5RD28, Q5REZ0, Q5TAH2, Q61168, Q6AXT9, Q6GV27, Q6GV28, Q7K1V5

Diamond homologs: Q3U3F9, Q66H29, Q9UJ42

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	35
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1477 predictions. Top by Δscore:

Variant	Effect	Δscore
3:170039051:G:GT	donor_gain	1.0000
3:170039051:G:T	donor_gain	1.0000
3:170038212:TCGGG:T	donor_loss	0.9900
3:170038214:GG:G	donor_gain	0.9900
3:170038215:GG:G	donor_gain	0.9900
3:170038216:G:GG	donor_gain	0.9900
3:170038216:GT:G	donor_loss	0.9900
3:170038218:GAGT:G	donor_loss	0.9900
3:170038909:GCGCA:G	acceptor_loss	0.9900
3:170038910:C:CA	acceptor_gain	0.9900
3:170038911:GCAGG:G	acceptor_loss	0.9900
3:170038912:CAG:C	acceptor_loss	0.9900
3:170038913:A:G	acceptor_loss	0.9900
3:170038914:GGT:G	acceptor_gain	0.9900
3:170038998:G:GT	donor_gain	0.9900
3:170039041:CCGG:C	donor_loss	0.9900
3:170039042:CGGT:C	donor_loss	0.9900
3:170039043:GGTAA:G	donor_loss	0.9900
3:170039044:G:A	donor_loss	0.9900
3:170039045:T:TC	donor_loss	0.9900
3:170038913:A:AG	acceptor_gain	0.9800
3:170038913:AGGT:A	acceptor_gain	0.9800
3:170038914:G:GG	acceptor_gain	0.9800
3:170038914:GGTG:G	acceptor_gain	0.9800
3:170039002:G:GT	donor_gain	0.9800
3:170039044:G:GG	donor_gain	0.9800
3:170038212:TCGG:T	donor_gain	0.9700
3:170038341:G:T	donor_gain	0.9700
3:170038986:C:T	donor_gain	0.9700
3:170038016:GC:G	donor_gain	0.9600

AlphaMissense

2234 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:170084825:A:C	S285R	0.985
3:170084827:T:A	S285R	0.985
3:170084827:T:G	S285R	0.985
3:170084726:T:A	W252R	0.979
3:170084726:T:C	W252R	0.979
3:170084411:T:A	W147R	0.978
3:170084411:T:C	W147R	0.978
3:170084912:T:A	W314R	0.975
3:170084912:T:C	W314R	0.975
3:170084807:T:A	W279R	0.974
3:170084807:T:C	W279R	0.974
3:170084914:G:C	W314C	0.972
3:170084914:G:T	W314C	0.972
3:170084800:T:A	N276K	0.968
3:170084800:T:G	N276K	0.968
3:170084076:A:T	K35I	0.959
3:170084903:T:C	F311L	0.957
3:170084905:T:A	F311L	0.957
3:170084905:T:G	F311L	0.957
3:170084507:A:C	S179R	0.942
3:170084509:C:A	S179R	0.942
3:170084509:C:G	S179R	0.942
3:170084089:T:A	N39K	0.939
3:170084089:T:G	N39K	0.939
3:170084169:A:C	D66A	0.937
3:170084307:T:A	V112D	0.937
3:170084907:T:A	V312D	0.935
3:170084714:T:C	F248L	0.929
3:170084716:T:A	F248L	0.929
3:170084716:T:G	F248L	0.929

dbSNP variants (sampled 300 via entrez): RS1000030836 (3:170041073 G>C), RS1000057285 (3:170038669 T>C,G), RS1000077320 (3:170038006 T>C), RS1000118382 (3:170045479 T>C), RS1000195728 (3:170037765 C>T), RS1000196286 (3:170083501 T>C,G), RS1000210527 (3:170065615 G>A), RS1000246597 (3:170070334 T>C), RS1000254910 (3:170052548 G>A), RS1000255937 (3:170044186 T>G), RS1000406129 (3:170051104 A>G), RS1000440857 (3:170050853 A>G), RS1000485610 (3:170036292 T>A), RS1000551188 (3:170083803 A>G,T), RS1000602449 (3:170071516 G>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002936_2	Cadmium levels	4.000000e-06
GCST004713_2	Testicular germ cell tumor	4.000000e-09
GCST008479_7	Psoriasis	1.000000e-12

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1777664 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Class A Orphans with emerging pharmacology

Binding affinities (BindingDB)

66 measured of 66 human assays (66 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
Trans-2-(3-((2′-fluoro-5′-phenoxy-[1,1′-biphenyl]-4-yl)oxy)cyclobutyl)acetic acid	EC50	110 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(2-fluoro-5-propan-2-yloxyphenyl)phenyl]cyclobutyl]acetic acid	EC50	120 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-[2,3-difluoro-5-(3-fluorophenoxy)phenyl]phenyl]cyclobutyl]oxyacetic acid	EC50	130 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-(3-(2′-Fluoro-5′-isopropoxy-[1,1′-biphenyl]-4-yl)cyclobutyl)acetic acid	EC50	140 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-(3-(Trans-1-methyl-3-(3-phenoxyphenyl)cyclobutyl)propoxy)acetic acid	EC50	150 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Cis-2-(-3-(2′-fluoro-5′-phenoxy-[1,1′-biphenyl]-4-yl)cyclobutoxy)acetic acid	EC50	170 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-(3-(Trans-3-(3-phenoxyphenyl)cyclobutyl)propoxy)acetic acid	EC50	170 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Cis-2-(3-(2′-fluoro-5′-(3-fluorophenoxy)-[1,1′-biphenyl]-4-yl)cyclobutoxy)acetic acid	EC50	230 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Cis-2-(3-(2′,3′-difluoro-5′-(4-fluorophenoxy)-[1,1′-biphenyl]-4-yl)cyclobutoxy)acetic acid	EC50	240 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Cis-2-(3-(2′-fluoro-5′-((6-methylpyridin-3-yl)oxy)-[1,1′-biphenyl]-4-yl)cyclobutoxy) acetic acid	EC50	270 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-[2,3-difluoro-5-(3-fluoro-4-methylphenoxy)phenyl]phenyl]cyclobutyl]oxyacetic acid	EC50	290 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Cis-2-(3-((2′-fluoro-5′-phenoxy-[1,1′-biphenyl]-4-yl)oxy)cyclobutyl)acetic acid	EC50	330 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-[2-chloro-5-(3-fluorophenoxy)-3-pyridinyl]phenyl]cyclobutyl]oxyacetic acid	EC50	360 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(5-cyclopentyloxy-2-fluorophenyl)phenyl]cyclobutyl]oxyacetic acid	EC50	410 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Trans-2-(3-(2′-fluoro-5′-phenoxy-[1,1′-biphenyl]-4-yl)cyclobutoxy)acetic acid	EC50	410 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-[2-fluoro-5-[(2-methyl-1,3-thiazol-5-yl)oxy]phenyl]phenyl]cyclobutyl]oxyacetic acid	EC50	420 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-(3-(Cis-3-(3-phenoxyphenyl)cyclobutyl)propoxy)acetic acid	EC50	420 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(3-methyl-5-propan-2-yloxyphenyl)phenyl]cyclobutyl]oxyacetic acid	EC50	430 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
4-(Cis-3-(3-phenoxybenzyloxy)cyclobutyl)butanoic acid	EC50	430 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Trans-3-((2′-fluoro-5′-phenoxy-[1,1′-biphenyl]-4-yl)oxy)cyclobutanecarboxylic acid	EC50	440 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
3-((2′-Fluoro-5′-isopropoxy-[1,1′-biphenyl]-4-yl)methylene)cyclobutanecarboxylic acid	EC50	460 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
3-((Cis-3-(3-phenoxybenzyloxy)cyclobutyl)methoxy)propanoic acid	EC50	470 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-[2-methoxy-5-(trifluoromethoxy)phenyl]phenyl]cyclobutyl]oxyacetic acid	EC50	480 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(2-fluoro-5-pyridin-2-yloxyphenyl)phenyl]cyclobutyl]oxyacetic acid	EC50	490 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
3-((2′-Fluoro-5′-isopropoxy-[1,1′-biphenyl]-4-yl)methyl)cyclobutanecarboxylic acid	EC50	500 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-(3-(Cis-3-(3-phenoxybenzyloxy)cyclobutyl)propoxy)acetic acid	EC50	520 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(2-fluoro-5-propan-2-yloxyphenyl)phenyl]cyclobutyl]oxyacetic acid	EC50	530 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-[2,3-difluoro-5-(4-methylphenoxy)phenyl]phenyl]cyclobutyl]oxyacetic acid	EC50	540 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-[2-fluoro-5-(trifluoromethoxy)phenyl]phenyl]cyclobutyl]oxyacetic acid	EC50	550 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-[2-fluoro-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]phenyl]cyclobutyl]oxyacetic acid	EC50	550 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(3-chloro-5-propan-2-yloxyphenyl)phenyl]cyclobutyl]oxyacetic acid	EC50	560 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[[4-(2-fluoro-5-propan-2-yloxyphenyl)phenyl]methyl]cyclobutyl]acetic acid	EC50	560 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
3-(3-(Cis-1-methyl-3-(3-phenoxyphenyl)cyclobutyl)propoxy)propanoic acid	EC50	570 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(3-propan-2-yloxyphenyl)phenyl]cyclobutyl]oxyacetic acid	EC50	590 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Cis-3-(3-(2′-fluoro-5′-isopropoxy-[1,1′-biphenyl]-4-yl)cyclobutyl)propanoic acid	EC50	650 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-(3-((2′-Fluoro-5′-isopropoxy-[1,1′-biphenyl]-4-yl)methyl)cyclobutyl)acetic acid	EC50	650 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(2-fluoro-5-pyridin-3-yloxyphenyl)phenyl]cyclobutyl]oxyacetic acid	EC50	660 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-(2-(3-(3-Phenoxybenzyloxy)cyclobutyl)ethoxy)acetic acid	EC50	700 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Cis-2-(3-(2′-fluoro-5′-(p-tolyloxy)-[1,1′-biphenyl]-4-yl)cyclobutoxy)acetic acid	EC50	710 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-(3-(Cis-1-methyl-3-(3-phenoxyphenyl)cyclobutyl)propoxy)acetic acid	EC50	740 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Cis-2-(3-(5′-(cyclohexyloxy)-2′-fluoro-[1,1′-biphenyl]-4-yl)cyclobutoxy)acetic acid	EC50	760 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
3-((2′-Fluoro-5′-isopropoxy-[1,1′-biphenyl]-4-yl)methyl)cyclobutanecarboxylic acid	EC50	790 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(2,6-difluoro-3-propan-2-yloxyphenyl)phenyl]cyclobutyl]oxyacetic acid	EC50	800 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(3-benzoylphenyl)phenyl]cyclobutyl]oxyacetic acid	EC50	830 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(3-chloro-5-methoxyphenyl)phenyl]cyclobutyl]oxyacetic acid	EC50	880 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-[2-chloro-5-(trifluoromethoxy)phenyl]phenyl]cyclobutyl]oxyacetic acid	EC50	900 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[[4-(2-fluoro-5-propan-2-yloxyphenyl)phenyl]methyl]cyclobutyl]acetic acid	EC50	940 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
2-[3-[4-(2-fluoro-3-propan-2-yloxyphenyl)phenyl]cyclobutyl]oxyacetic acid	EC50	1020 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Trans-2-(((3-(3-phenoxyphenyl)cyclobutyl)methoxy)methyl)cyclopropanecarboxylic acid	EC50	1260 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators
Cis2-(3-(2′-fluoro-5′-((tetrahydro-2H-pyran-3-yl)oxy)-[1,1′-biphenyl]-4-yl)cyclobutoxy)acetic acid	EC50	1400 nM	US-10023519: Cyclobutane containing carboxylic acid GPR120 modulators

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	8
Cyclosporine	increases expression, decreases expression	3
potassium chromate(VI)	affects cotreatment, decreases expression, increases expression	2
entinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	2
Tretinoin	increases expression	2
Aflatoxin B1	decreases expression, affects expression	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
bisphenol A	affects cotreatment, decreases methylation	1
trichostatin A	increases expression	1
butyraldehyde	increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
pentanal	increases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	affects expression	1
2-palmitoylglycerol	increases expression	1
K 7174	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
MT19c compound	increases expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Aldehydes	increases expression	1
Carbamazepine	affects expression	1
Cisplatin	decreases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1781115	Binding	Inhibition of GPCR-1 at 10 uM	Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes. — Bioorg Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.